



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **Pere Domingo**

Organisation/Company: Hospital de la Santa Creu I Sant Pau

Country: Spain

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2008-(current)	Janssen & Cilag	Prezista, Intelence, Rezolsta, Edurant, Symtuza	HIV infection
01/2004-(current)	Gilead Sciences	Truvada, Atripla, Stribild, Genvoya, Descovy, Odefsey, Biktarvy	HIV infection
01/2000-12/2002	Abbott Laboratories	Kaletra	HIV infection
01/2000-12/2002	Boehringer Ingelheim	Viramune	HIV infection
01/2010-(current)	Viiv Healthcare	Kivexa, Tivicay, Triumeq, Dovato	HIV infection
04/1997-12/2014	Bristol, Myers & Squibb	Atripla, Reyataz	HIV infection
01/2011-12/2011	Ferrer International	Thesamorelin	Lipohypertrophy
01/2008-(current)	Merck, Sharp & Dohme	Isentress, Isentress HD, Pfifeltro, Delstrigo	HIV infection
04/2020-(current)	Roche	Tocilizumab	COVID-19
04/2020-(current)	Roche	Tocilizumab, casirivimab, imdevimab	COVID-19

Classified as public by the European Medicines Agency

2

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2011-(current)	ViiV Healthcare	Dolutegravir, Dovato	HIV infection
05/2013-(current)	Janssen & Cilag	Darunavir, Symtuza	HIV Infection
04/2015-(current)	Gilead Sciences	Tenofovir, Biktarvy	HIV infection
04/2016-(current)	Merck Sharp & Dohme	Doravirine	HIV infection
04/2020-(current)	Roche	Tocilizumab	COVID-19

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Repurposing of a medicinal product

No interest declared

## 2.10 Any other interests or facts

None

## 2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Pere Domingo Pedrol
Date:	2022-10-12

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*